Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.
ESAB (ESAB)
Trailing 12-Month GAAP Operating Margin: 12.1%
Having played a significant role in the construction of the iconic Sydney Opera House, ESAB (NYSE:ESAB) manufactures and sells welding and cutting equipment for numerous industries.
Why Are We Wary of ESAB?
- Muted 4.2% annual revenue growth over the last two years shows its demand lagged behind its industrials peers
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Waning returns on capital imply its previous profit engines are losing steam
ESAB is trading at $74.02 per share, or 12.5x forward P/E. Check out our free in-depth research report to learn more about why ESAB doesn’t pass our bar.
United Therapeutics (UTHR)
Trailing 12-Month GAAP Operating Margin: 44.4%
Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.
Why Is UTHR Not Exciting?
- Sales are projected to tank by 3.2% over the next 12 months as demand evaporates
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 6.6 percentage points
- 1.8 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
At $485.55 per share, United Therapeutics trades at 17.8x forward P/E. If you’re considering UTHR for your portfolio, see our FREE research report to learn more.
Payoneer (PAYO)
Trailing 12-Month GAAP Operating Margin: 10.4%
Founded during the early days of global e-commerce in 2005 to solve international payment challenges, Payoneer (NASDAQ:PAYO) provides financial technology services that enable small and medium-sized businesses to send and receive payments globally across borders.
Why Does PAYO Worry Us?
- Incremental sales over the last two years were much less profitable as its earnings per share fell by 5.2% annually while its revenue grew
- Low return on equity reflects management’s struggle to allocate funds effectively
Payoneer’s stock price of $7.12 implies a valuation ratio of 18.9x forward P/E. Read our free research report to see why you should think twice about including PAYO in your portfolio.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.